Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531572 | 0.91 | POLB (0.54) | CHKAALDH1A1POLBTP53RXFP1 | |
| SCHEMBL12269651 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TP53MAPTPRMT5WDR77 | |
| SCHEMBL2407502 | 0.91 | FPR2 (0.52) | ALDH1A1POLBTP53RXFP1MAPT | |
| SCHEMBL2407378 | 0.90 | MAPT (0.51) | ALDH1A1POLBTP53RXFP1MAPT | |
| SCHEMBL2531850 | 0.89 | ALDH1A1 (0.57) | CHKAALDH1A1POLBTP53RXFP1 | |
| SCHEMBL2404223 | 0.87 | TP53 (0.52) | ALDH1A1POLBTP53MAPTSMN1; SMN2 | |
| SCHEMBL2534636 | 0.85 | CHKA (0.68) | CHKAALDH1A1POLBTP53MAPT | |
| SCHEMBL2405052 | 0.85 | PTPN1 (0.55) | ALDH1A1TP53RXFP1MAPTPRMT5 | |
| SCHEMBL2530593 | 0.85 | CHKA (0.70) | CHKAALDH1A1POLBTP53RXFP1 | |
| SCHEMBL2530988 | 0.84 | POLB (0.52) | CHKAALDH1A1POLBTP53RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | CHKA, CHKB, CEPT1 | CHKA 1/4885ALDH1A1 1482/4885POLB 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.